A composition for increasing myocardial vitality, improving myocardial cell metabolism and heart failure and its application

Abstract

The present invention discloses a composition for improving myocardial vitality, myocardial cell metabolism and heart failure and its application. The composition comprises the following components: trisodium salt of fructose 1,6-diphosphate, myocardial peptide, mangosteen powder, elderberry fruit powder, black fruit glandular rib aronia fruit concentrated powder, noni pulp powder, taurine, oligosaccharides, D-ribose, ginseng powder, daidai pollen, vitamins, and minerals. The present invention belongs to the field of medical technology. The composition has high safety, rigorous and scientific compatibility, and implements the core concept of "from cause to effect, syndrome differentiation and treatment". By improving antioxidant capacity and hypoxia tolerance to achieve the purpose of improving myocardial vitality, promoting myocardial cell energy metabolism, and reducing myocardial infarction area, it has a good effect on improving and conditioning cardiovascular and cerebrovascular diseases such as heart failure, myocardial infarction, myocardial ischemic injury, angina pectoris and arrhythmia.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to a composition for improving myocardial vitality, myocardial cell metabolism and heart failure, and application thereof. Background Art

[0002] Myocardial protection plays a very important role in the development of cardiac surgery. Data show that many changes that occur in ischemic myocardial cells, such as increased calcium levels, membrane damage, free radical production, decreased adenosine triphosphate (ATP) levels, oxygen depletion, etc., cause metabolic or hypoxic stress, and at the same time, the endogenous protection mechanism in the cell will be activated, leading to myocardial cell apoptosis and myocardial tissue necrosis. Among them, oxygen free radicals can cause myocardial damage. The way free radicals damage the myocardium is to cause oxidation, cross-linking, denaturation and degradation of DNA, RNA, protein, amino acids and polysaccharide polymers in cells, but the most important process leading to myocardial cell damage is that free radicals act on unsaturated fatty acids on the cell membrane to form lipid peroxides, which cause membrane protein dysfunction, lead to enzyme activity loss, inhibit the generation of myocardial energy, and cause irreversible protein damage.

[0003] Myocardial protection is a comprehensive measure. The key is to minimize energy consumption, ensure energy supply, prevent and treat ischemia-reperfusion injury, and reduce inflammatory response after extracorporeal circulation. In recent years, it is believed that in addition to maintaining appropriate concentrations of potassium and magnesium in cardioplegia solution, the addition of glucose, insulin, adenosine triphosphate or creatine phosphate and other basic energy metabolism substances can provide energy to maintain the metabolic needs during the blockade of myocardial ischemia. It is generally believed that the pH value should be above 7.4, which can buffer and counteract acidosis caused by anaerobic metabolism. Some scholars have pointed out that adding an appropriate amount of procaine, adrenocortical hormones and other drugs can stabilize cell membranes, and adding calcium blocking drugs such as verapamil and nifedipine can reduce calcium ion influx during reperfusion. Some studies have also pointed out that the use of free radical scavengers or substances that inhibit free radicals can counter the generation of free radicals and protect the myocardium, that is, the use of free radical scavengers for myocardial protection. As long as the oxygen free radicals can be minimized, the myocardium can be protected to a greater extent. Although myocardial protection methods are constantly improving in clinical practice, the myocardial protective effects of the drugs used are still unsatisfactory. Therefore, it is necessary to research and develop more effective drugs to improve myocardial cell metabolism and enhance myocardial vitality. Summary of the invention

[0004] In view of the deficiencies of the prior art, the present invention provides a composition for improving myocardial vitality, myocardial cell metabolism and heart failure and its application.

[0005] In order to achieve the purpose of the present invention, the present invention is implemented by the following technical solutions:

[0006] A composition for improving myocardial vitality, myocardial cell metabolism and heart failure, comprising, by weight: 0.05-0.3 parts of trisodium fructose 1,6-diphosphate, 1-4 parts of myocardial peptide, 1.2-7.5 parts of antioxidant composition, 0.1-0.5 parts of taurine, 5-10 parts of oligosaccharides, 1-5 parts of D-ribose, 0.1-0.5 parts of ginseng powder, and 0.1-0.5 parts of daidai pollen; the antioxidant composition is 0.1-0.5 parts of mangosteen powder, 0.5-2 parts of elderberry powder, 0.5-2 parts of aronia suffruticosa fruit concentrated powder, and 0.1-3 parts of noni pulp powder.

[0007] Furthermore, a composition for improving myocardial vitality, improving myocardial cell metabolism and heart failure comprises, by weight: 0.2 parts of trisodium fructose 1,6-diphosphate, 3 parts of myocardial peptide, 3.8 parts of antioxidant composition, 0.3 parts of taurine, 7 parts of oligosaccharides, 4 parts of D-ribose, 0.4 parts of ginseng powder, and 0.4 parts of daidai pollen; the antioxidant composition is 0.3 parts of mangosteen powder, 1 part of elderberry powder, 1 part of aronia suffruticosa fruit concentrated powder, and 1.5 parts of noni pulp powder.

[0008] Furthermore, the myocardial peptide is one or more of animal myocardial peptides such as deer myocardial peptide, bovine myocardial peptide, yak myocardial peptide, etc.

[0009] Furthermore, the oligosaccharide is one or more of maltooligosaccharide, xylooligosaccharide, fructooligosaccharide and isomaltooligosaccharide.

[0010] Furthermore, the composition also includes: 0.05-0.3 parts of vitamins and / or 0.05-0.3 parts of minerals.

[0011] Furthermore, the vitamins include one or more of vitamin A, vitamin D, vitamin C, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, and niacin, and the minerals include one or more of sodium, magnesium, potassium, calcium, iron, and zinc.

[0012] After exploration and research, it was found that the composition of the present invention exhibits a better myocardial protective effect under a specific combination of raw materials.

[0013] Therefore, further, the present invention provides an oral preparation comprising the composition, and the composition is added with conventional excipients and prepared according to conventional processes to obtain the oral preparation, and the oral preparation includes any one of powders, tablets, granules, capsules, solutions, emulsions, and suspensions.

[0014] Furthermore, the present invention provides use of the composition or the preparation in preparing a product for preventing and treating myocardial injury.

[0015] Furthermore, the myocardial injury is myocardial ischemia.

[0016] Furthermore, a method for preparing a composition for improving myocardial vitality, myocardial cell metabolism and heart failure comprises the following steps:

[0017] Step 1: Mix 1,6-diphosphate fructose trisodium salt, taurine, and vitamins according to corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water as the mixture 1, and stir at room temperature for 5-10 minutes;

[0018] Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder, daidai pollen, and minerals in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes;

[0019] Step 3: If granulation is performed, preheat a one-step granulator to above 60°C, mix mixture 1 and mixture 2, stir evenly and then granulate. During the granulation process, the inlet air temperature is 70°C-80°C, the outlet temperature is 50°C-60°C, the granulation time is 2-3 hours, and the granule moisture is ≤3.0% to obtain a composition;

[0020] If a solution preparation is to be carried out, the mixture 1 and the mixture 2 are mixed, stirred and heated for 0.5-2 hours, and homogenized using a high-speed homogenizer for 6-10 minutes to obtain a composition.

[0021] The effects of each component in the present invention are as follows:

[0022] Trisodium fructose 1,6-diphosphate: Fructose 1,6-diphosphate is an important intermediate in the sugar metabolism process. It can improve myocardial energy metabolism, stabilize cell membranes, reduce inflammatory responses, inhibit oxygen free radicals, reduce extracellular Ca2+ concentrations, inhibit arrhythmias, etc. It can reduce damage to ischemic myocardium and has achieved good results in animal experiments and clinical studies.

[0023] Myocardial peptide: Myocardial peptide helps to restore the prognosis of patients with heart failure. Myocardial peptide can directly act on myocardial cells and promote the repair of damaged myocardium. At the same time, myocardial peptide has a good effect on improving myocardial ischemia, can help patients repair damage to the ultrastructure of the heart, and can also help reduce myocardial oxygen consumption, can play a role in nourishing the myocardium, can better improve myocardial function, and help reduce the occurrence of some heart diseases.

[0024] Mangosteen powder: Mangosteen is rich in vitamins and minerals, such as vitamin C, potassium, iron and antioxidants, and is known as the "Queen of Fruits". Its rich antioxidants can help the body resist the damage of free radicals, slow down the aging process, and keep the skin young. Mangosteen is good for heart health. Its rich potassium helps regulate blood pressure, maintain normal heart function, and reduce the risk of cardiovascular disease. Mangosteen can help reduce the risk of stroke or myocardial infarction.

[0025] Elderberry powder: Elderberry is rich in polyphenols, which can remove free radicals and thus achieve the purpose of anti-oxidation. Appropriate intake of elderberry can help prevent skin aging and reduce the risk of cardiovascular disease.

[0026] Aronia nigra fruit concentrate powder: Aronia nigra fruit is rich in antioxidants, such as anthocyanins, which can effectively fight free radicals and reduce oxidative damage to blood vessel walls, thereby improving blood circulation and preventing the occurrence of cardiovascular and cerebrovascular diseases. In addition, it can soften blood vessels, control blood pressure, and has a good improvement effect on cardiovascular and cerebrovascular diseases such as hypertension, and can effectively assist in improving cardiovascular and cerebrovascular health.

[0027] Noni fruit pulp powder: Noni fruit has antioxidant, immunity-enhancing, brain and intelligence-enhancing effects. Noni fruit is a natural antioxidant with antioxidant activity and myocardial cell protection, which can regulate impaired energy metabolism and slow down the progression of heart failure.

[0028] Taurine: Taurine can protect the myocardium and enhance the function of the heart. When calcium ions flow into myocardial cells excessively, it will cause coronary heart disease. Long-term intake of taurine can effectively control the amount of calcium ions in it.

[0029] Oligosaccharides: Oligosaccharides can lower cholesterol levels, reduce the risk of cardiovascular diseases, and also help maintain stable blood pressure. They are easy to digest and low in sweetness, and can extend energy supply time, enhance body endurance, resist fatigue, and enhance immunity.

[0030] Ribose: The biological functions of D-ribose are very important, the most important of which is to participate in the biosynthesis of ATP, which can increase the synthesis rate of ATP, thereby accelerating the energy metabolism process and enhancing the body's energy supply and exercise capacity. In the treatment of cardiovascular diseases such as myocardial infarction and heart failure, D-ribose can improve the energy metabolism of myocardial cells and promote the regeneration and repair of myocardial cells, thereby achieving the purpose of treatment. Clinical trials have shown that oral D-ribose can improve the cardiac function of patients with heart failure.

[0031] Ginseng: Ginseng generally has the effects of enhancing myocardial contractility, protecting cardiovascular system, resisting arrhythmia, resisting myocardial ischemia, and improving myocardial metabolism. Studies have shown that the mechanism of ginsenosides in resisting myocardial ischemia and reperfusion injury is to promote myocardial production and release of prostaglandins, inhibit the production of thromboxane A2, and protect myocardial cells through anti-oxidant free radicals and anti-lipid peroxidation. Ginseng also has the effects of greatly replenishing vital energy, tonifying the spleen and lungs, promoting body fluid, and calming the mind and improving intelligence.

[0032] Daidai pollen can calm and strengthen the heart, improve heart function, increase myocardial blood supply, and prevent the occurrence of many common heart diseases such as bradycardia, myocardial ischemia, and heart failure. Daidai pollen also has antioxidant effects.

[0033] Minerals and vitamins can improve myocardial nutrition.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The composition of the present invention fully inhibits oxygen free radicals through the antioxidant composition (mangosteen powder, elderberry powder, black fruit glandular rib fruit concentrated powder, noni pulp powder), and is matched with trisodium 1,6-diphosphate fructose, D-ribose and oligomaltose to enhance the energy metabolism of myocardial cells. Myocardial peptide, ginseng powder and daidai pollen further improve myocardial ischemia. At the same time, the amount of calcium ions is controlled by trisodium 1,6-diphosphate fructose and taurine. Comprehensive coordination from multiple aspects can effectively improve the antioxidant capacity and hypoxia tolerance, reduce the area of ​​myocardial infarction, and is beneficial to improving myocardial vitality, improving myocardial cell energy metabolism and improving heart failure, thereby playing a role in preventing and treating myocardial ischemic damage. The composition has high safety, rigorous and scientific compatibility, and implements the core concept of "cause and effect, syndrome differentiation and treatment", and has good effects on improving and regulating cardiovascular and cerebrovascular diseases such as heart failure, myocardial infarction, myocardial ischemic damage, angina pectoris and arrhythmia. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 is the DPPH free radical scavenging rate of mice in each group.

[0037] Figure 2 is the myocardial infarction area of ​​mice with myocardial ischemia in each group. DETAILED DESCRIPTION

[0038] The present invention is described clearly and completely below in conjunction with specific embodiments, but the present invention is not limited thereto. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention. Example 1

[0039] A composition for improving myocardial vitality, myocardial cell metabolism and heart failure, comprising, by weight: 0.2 parts of trisodium fructose 1,6-diphosphate, 3 parts of deer myocardin, an antioxidant composition (0.3 parts of mangosteen powder, 1 part of elderberry powder, 1 part of aronia suffruticosa fruit concentrated powder, 1.5 parts of noni pulp powder), 0.3 parts of taurine, 7 parts of maltooligosaccharide, 4 parts of D-ribose, 0.4 parts of ginseng powder and 0.4 parts of daidai pollen.

[0040] The preparation is specifically carried out in the following steps: Step 1: Mix 1,6-diphosphate fructose trisodium salt, taurine, and vitamins in corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water of the mixture 1, and stir at room temperature for 5-10 minutes;

[0041] Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder, daidai pollen, and minerals in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes;

[0042] Step 3: Mix mixture 1 and mixture 2, stir and heat for 0.5-2 hours, and homogenize using a high-speed homogenizer for 6-10 minutes to obtain a composition. Example 2

[0043] A composition for improving myocardial vitality, myocardial cell metabolism and heart failure, comprising, by weight: 0.05 parts of trisodium fructose 1,6-diphosphate, 1 part of bovine myocardial peptide, an antioxidant composition (0.1 parts of mangosteen powder, 0.5 parts of elderberry powder, 0.5 parts of aronia suffruticosa fruit concentrated powder, 0.1 parts of noni pulp powder), 0.1 parts of taurine, 5 parts of xylo-oligosaccharides, 1 part of D-ribose, 0.1 parts of ginseng powder, 0.1 parts of daidai pollen, vitamins (0.05 parts of vitamin C, 0.05 parts of vitamin B6), and minerals (0.05 parts of sodium chloride and 0.05 parts of magnesium chloride).

[0044] Specifically prepared by the following steps:

[0045] Step 1: Mix 1,6-diphosphate fructose trisodium salt, taurine, and vitamins according to corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water as the mixture 1, and stir at room temperature for 5-10 minutes;

[0046] Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder, daidai pollen, and minerals in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes;

[0047] Step 3: Mix mixture 1 and mixture 2, stir and heat for 0.5-2 hours, and homogenize using a high-speed homogenizer for 6-10 minutes to obtain a composition. Example 3

[0048] A composition for improving myocardial vitality, myocardial cell metabolism and heart failure, comprising, by weight: 0.3 parts of trisodium fructose 1,6-diphosphate, 4 parts of yak myocardial peptide, an antioxidant composition (0.5 parts of mangosteen powder, 2 parts of elderberry powder, 2 parts of aronia suffruticosa fruit concentrated powder, 3 parts of noni pulp powder), 0.6 parts of taurine, oligosaccharides (5 parts of isomaltooligosaccharides, 5 parts of fructooligosaccharides), 5 parts of D-ribose, 0.5 parts of ginseng powder and 0.5 parts of daidai pollen.

[0049] Specifically prepared by the following steps:

[0050] Step 1: Mix 1,6-diphosphate fructose trisodium salt, taurine, and vitamins according to corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water as the mixture 1, and stir at room temperature for 5-10 minutes;

[0051] Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder, daidai pollen, and minerals in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes;

[0052] Step 3: Mix mixture 1 and mixture 2, stir and heat for 0.5-2 hours, and homogenize using a high-speed homogenizer for 6-10 minutes to obtain a composition.

[0053] Comparative Example 1: Compared with Example 1, vitamin C is used instead of the antioxidant composition (mangosteen powder, elderberry powder, aronia nigra fruit concentrated powder and noni pulp powder), and the amount of vitamin C used is 3.8 parts.

[0054] Comparative Example 2: Compared with Example 1, the antioxidant composition lacks mangosteen powder and elderberry powder, and the amounts of Aronia nigra fruit concentrated powder and Noni pulp powder are adjusted to 1.9 parts and 1.9 parts respectively.

[0055] Comparative Example 3: Compared with Example 1, the antioxidant composition lacks Aronia melanocarpa fruit concentrated powder and Noni pulp powder, and the amounts of mangosteen powder and elderberry powder are adjusted to 1.9 parts and 1.9 parts, respectively.

[0056] Comparative Example 4: Compared with Example 1, trisodium fructose 1,6-diphosphate and D-ribose are missing, and the amount of maltooligosaccharide is adjusted to 11.2 parts.

[0057] Comparative Example 5: Compared with Example 1, taurine is missing, and the amount of trisodium fructose 1,6-diphosphate is adjusted to 0.5 parts.

[0058] Comparative Example 6: Compared with Example 1, deer myocardin is missing and the content of ginseng powder is adjusted to 3.4 parts.

[0059] Test Example 1 Antioxidant Capacity Test of the Composition for Improving Myocardial Vitality, Myocardial Cell Metabolism and Heart Failure of the Present Invention

[0060] Scavenging effect on DPPH free radicals

[0061] The samples of Examples 1-3 and Comparative Examples 1-6 were prepared into 200 μg / mL samples using pure water as solvent, centrifuged at 8000 r / min at room temperature for 5 min, and the supernatant was taken as the test solution. The DPPH mother solution and anhydrous ethanol were prepared into DPPH working solution in a volume ratio of 1:5. The samples were added according to the instructions of the DPPH free radical scavenging ability kit, mixed well, and allowed to stand at room temperature in the dark for 30 min, and the absorbance at 515 nm was measured. The absorbance values ​​of the blank well, control well, and test well were recorded as A0, A1, and A2, respectively. t DPPH free radical scavenging rate calculation formula: DPPH free radical scavenging rate (%) = [A0-(A t -A1)] / A0×100%.

[0062] The DPPH free radical scavenging rate test is one of the important indicators for determining the antioxidant capacity of samples. The scavenging effects of Examples 1-3 and Comparative Examples 1-6 on DPPH free radicals are shown in Figure 1 .Depend on Figure 1 It can be seen that the antioxidant composition added to the product of the present application can achieve a scavenging rate of DPPH free radicals of more than 76.34%, which is better than Comparative Example 1 (Vitamin C, 70.84%), indicating that the antioxidant composition of the present application has a strong antioxidant capacity. The improvement of antioxidant capacity can minimize oxygen free radicals, thereby protecting the myocardium to a greater extent. At the same time, the antioxidant composition of the present application uses mangosteen powder, elderberry powder, black fruit glandular rib aronia fruit concentrated powder and noni pulp powder to scavenging DPPH free radicals. It is better than Comparative Example 2 (combination of mangosteen powder and elderberry powder, 65.97%) and Comparative Example 3 (combination of black fruit glandular rib aronia fruit concentrated powder and noni pulp powder 67.18%), indicating that the antioxidant compositions of the present application have synergistic effects. The raw material adjustment of Comparative Examples 4-6 also has a certain degree of influence on the antioxidant capacity of the entire composition, but the influence effect is lower than that of the antioxidant composition.

[0063] Experimental Example 2: Investigation of the efficacy of the composition of the present invention for improving myocardial vitality, myocardial cell metabolism and heart failure

[0064] 2.1 Hypoxia tolerance test

[0065] SPF male Kunming mice aged 6 to 8 weeks were selected and randomly divided into groups, with 10 mice in each group. The blank group and the model group were gavaged with an equal volume of normal saline, the positive drug group was gavaged with 0.1% propranolol hydrochloride solution, and the samples of Examples 1-3 and Comparative Examples 1-6 were gavaged with 0.5 g / kg body weight. Once a day for 7 consecutive days, 30 minutes after the last administration, put it into a 250ml wide-mouth bottle containing 10 g of soda lime, put one mouse in each bottle, apply vaseline oil to the bottle mouth to prevent air leakage, and start recording after sealing with a cover. When the mouse stops breathing and the abdomen no longer rises and falls, the calculation time is terminated, and the survival time of the mouse is calculated. Except for the blank group, all other groups were subcutaneously injected with 20 mg / kg of isoproterenol 15 minutes before being placed in the bottle to increase myocardial oxygen consumption. Survival time extension rate % = (average survival time of each group (min)-average survival time of the model group (min)) / average survival time of the model group (min) × 100%.

[0066] Table 1 Comparison of hypoxia tolerance survival time in each group

[0067]

[0068] Hypoxia is one of the main factors leading to myocardial ischemia, myocardial infarction and other diseases. Hypoxia can directly affect the metabolism of cardiac cells, leading to abnormal metabolism of cardiac cells, thereby affecting the normal operation of the heart. As shown in the results of Table 1, compared with the model group, Examples 1-3 can significantly prolong the hypoxia-tolerant survival time of mice (p < 0.001), and are close to the extension rate of the positive control group. Although Comparative Examples 1-6 can also prolong the hypoxia-tolerant survival time to a certain extent, the effect is not as good as that of Examples 1-3. In the mouse hypoxia tolerance experiment, it can be seen that the longer the mouse survives, the better its hypoxia tolerance. The improvement of hypoxia tolerance can help improve myocardial vitality, improve myocardial cell metabolism and heart failure.

[0069] 2.2 Effects on myocardial infarction area in mice with myocardial ischemia

[0070] SPF male Kunming mice aged 6 to 8 weeks were selected and divided into 12 groups: blank group, model group, positive group (Di'ao Xinxuekang, 50 mg / kg), Example 1-3 and Comparative Example 1-6 (150 mg / kg), 10 mice in each group. The blank group and the model group were gavaged with equal volumes of distilled water once a day for 7 consecutive days. During the administration period, the mice were free to drink water and eat. The status of the mice was recorded during the administration period. Except for the blank group, the remaining groups were intraperitoneally injected with isoproterenol (60 mg / kg) for 3 consecutive days on the 8th to 10th day after gavage. After the mouse modeling was completed, the mice were fasted, the status of the mice was recorded after 24 hours, and the mice were killed to collect the mouse hearts. The heart tissue was washed, and then the heart tissue was evenly cut into 5 pieces in the vertical direction, placed in TTC staining solution, stained in a constant temperature water bath at 37°C for 15 minutes, and then fixed with 4% formaldehyde for 12 hours, and photographed and recorded. The non-infarcted part was stained red, and the infarcted part was stained white. Image-J was used for analysis to calculate the myocardial ischemic infarct area.

[0071] Table 2 Effects on myocardial infarction area in mice with myocardial ischemia

[0072]

[0073] Myocardial ischemia can affect myocardial cell activity, leading to reduced oxygen supply to the heart and abnormal myocardial energy metabolism. Figure 2 As shown in Table 2, the proportion of myocardial ischemic infarction area in the model group was significantly increased compared with the blank group, indicating that the modeling was successful. The myocardial infarction area of ​​the composition preparations prepared in Examples 1-3 of the present invention and the positive control group was significantly lower than that of the model group (P < 0.01), indicating that the composition of the present application can significantly reduce myocardial infarction. After adjusting the raw material composition, the effects of Comparative Examples 1-6 were all reduced compared with Example 1, and there was a significant difference, indicating that there is a certain synergistic effect between the raw materials of the present application, and after cooperating with each other, it can better exert its therapeutic effect of improving myocardial ischemic injury.

[0074] In summary, the components of the composition of the present invention can synergistically enhance their effectiveness, have good antioxidant capacity, can effectively improve hypoxia tolerance, reduce the area of ​​myocardial infarction, and are beneficial to improving myocardial vitality, myocardial cell metabolism and heart failure, thereby playing a role in preventing and treating myocardial ischemic damage, and has high safety.

[0075] The applicant declares that the above embodiments are used to illustrate the product, use and use of the present invention, but the present invention is not limited to the above detailed uses or use, that is, it does not mean that the present invention must rely on the above detailed uses and use to be realized. Personnel in the relevant technical field should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention and addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A composition for preventing and treating myocardial infarction, characterized in that: The composition is made of the following components in parts by weight: 0.05-0.3 parts of trisodium salt of fructose 1,6-diphosphate, 1-4 parts of myocardial peptide, 1.2-7.5 parts of antioxidant composition, 0.1-0.6 parts of taurine, 5-10 parts of oligosaccharides, 1-5 parts of D-ribose, 0.1-0.5 parts of ginseng powder, and 0.1-0.5 parts of daidai pollen; the antioxidant composition is 0.1-0.5 parts of mangosteen powder, 0.5-2 parts of elderberry powder, 0.5-2 parts of black fruit glandular rib aronia fruit concentrated powder, and 0.1-3 parts of noni pulp powder; the myocardial peptide is one or two of deer myocardial peptide and bovine myocardial peptide; the oligosaccharide is one or more of maltooligosaccharide, xylooligosaccharide, fructooligosaccharide, and isomaltooligosaccharide; The preparation method of the composition comprises the following steps: Step 1: Mix 1,6-diphosphate fructose trisodium salt and taurine in corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water as the mixture 1, and stir at room temperature for 5-10 minutes; Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder and daidai pollen in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes; Step 3: Mix the product of step 1 and the product of step 2, stir and heat for 0.5-2 hours, and homogenize using a high-speed homogenizer for 6-10 minutes to obtain a composition.

2. A composition for preventing and treating myocardial infarction according to claim 1, characterized in that: The composition is prepared from the following components in parts by weight: 0.2 parts of trisodium fructose 1,6-diphosphate, 3 parts of myocardial peptide, 3.8 parts of antioxidant composition, 0.3 parts of taurine, 7 parts of oligosaccharides, 4 parts of D-ribose, 0.4 parts of ginseng powder, and 0.4 parts of daidai pollen; the antioxidant composition is 0.3 parts of mangosteen powder, 1 part of elderberry powder, 1 part of aronia suffruticosa fruit concentrated powder, and 1.5 parts of noni pulp powder.

3. A composition for preventing and treating myocardial infarction, characterized in that: The composition is prepared from the following components in parts by weight: 0.05 parts of trisodium salt of fructose 1,6-diphosphate, 1 part of myocardial peptide, 1.2 parts of antioxidant composition, 0.1 parts of taurine, 5 parts of oligosaccharides, 1 part of D-ribose, 0.1 parts of ginseng powder, 0.1 parts of daidai pollen, 0.1 parts of vitamins and 0.1 parts of minerals; the antioxidant composition is 0.1 parts of mangosteen powder, 0.5 parts of elderberry powder, 0.5 parts of aronia suffruticosa fruit concentrated powder and 0.1 parts of noni pulp powder; the myocardial peptide is bovine myocardial peptide; the oligosaccharides are xylo-oligosaccharides; the vitamins are 0.05 parts of vitamin C and 0.05 parts of vitamin B6; the minerals are 0.05 parts of sodium chloride and 0.05 parts of magnesium chloride; The preparation method of the composition comprises the following steps: Step 1: Mix 1,6-diphosphate fructose trisodium salt, taurine, and vitamins according to corresponding amounts to obtain a mixture 1, add 4-5 times the amount of water as the mixture 1, and stir at room temperature for 5-10 minutes; Step 2: Mix the myocardial peptide, antioxidant composition, oligosaccharide, D-ribose, ginseng powder, daidai pollen, and minerals in corresponding amounts to obtain a second mixture, add 4-5 times the amount of water of the second mixture, heat and stir for 10-15 minutes, and homogenize with a high-speed homogenizer for 15-20 minutes; Step 3: If granulation is performed, preheat the one-step granulator to above 60°C, mix the product of step 1 and the product of step 2, stir evenly and then granulate. During the granulation process, the inlet air temperature is 70°C-80°C, the outlet temperature is 50°C-60°C, the granulation time is 2-3 hours, and the granule moisture is ≤3.0% to obtain a composition; If a solution preparation is performed, the product of step 1 and the product of step 2 are mixed, stirred and heated for 0.5-2 hours, and homogenized using a high-speed homogenizer for 6-10 minutes to obtain a composition.

4. An oral preparation for preventing and treating myocardial infarction, characterized in that: The composition according to any one of claims 1 to 3, wherein the oral preparation comprises one of powder, tablet, granule, capsule, solution, emulsion and suspension.

5. Use of the composition according to any one of claims 1 to 3 or the oral preparation according to claim 4 in the preparation of a product for preventing and treating myocardial infarction.

6. The use according to claim 5, characterized in that: The myocardial infarction is an infarction caused by myocardial ischemia.

Images